• AM 281: Selective CB1 Receptor Antagonist for Neuropharma...

  2026-03-30

  AM 281 delivers unmatched selectivity and potency for probing the CB1 cannabinoid receptor in memory, neuroprotection, and addiction models. With proven efficacy in cognitive dysfunction and traumatic brain injury studies, this tool from APExBIO accelerates translational neuropharmacology and experimental reproducibility.

• AM 281 and the CB1-CREB-GLT-1 Axis: Pioneering Neuroprote...

  2026-03-29

  Explore the unique mechanism of AM 281, a selective CB1 cannabinoid receptor antagonist, in modulating the CB1-CREB-GLT-1 pathway for advanced neuropharmacology research. This article uncovers novel neuroprotective strategies in traumatic brain injury and cognitive dysfunction, offering deeper insight beyond standard workflows.

• AM 281 and the CB1 Cannabinoid Receptor: Strategic Pathwa...

  2026-03-28

  Explore how the selective CB1 receptor antagonist and inverse agonist AM 281 is reshaping neuropharmacology research, from mechanistic insights in traumatic brain injury and addiction models to translational strategies addressing cognitive dysfunction. This article goes beyond conventional product guides, providing a visionary synthesis for bench-to-bedside neuroscience innovation.

• AM 281: Selective CB1 Cannabinoid Receptor Antagonist for...

  2026-03-27

  AM 281 is a potent and selective CB1 cannabinoid receptor antagonist and inverse agonist, enabling precise modulation of the cannabinoid signaling pathway. Its high selectivity and efficacy make it a gold-standard tool for neuropharmacology research, including memory impairment and cognitive dysfunction studies.

• AM 281 and the CB1-CREB Pathway: Advancing Cognitive Dysf...

  2026-03-27

  Explore how AM 281, a selective CB1 cannabinoid receptor antagonist, unlocks new opportunities for dissecting the CB1-CREB signaling pathway in neuropharmacology. This in-depth article reveals distinct mechanistic insights and translational applications for memory impairment and traumatic brain injury models.

• Strategic Mechanisms and Translational Opportunities: AM ...

  2026-03-26

  AM 281, a potent and selective CB1 cannabinoid receptor antagonist and inverse agonist from APExBIO, is redefining the landscape of neuropharmacological research. This thought-leadership article blends mechanistic insights, experimental validation, and strategic guidance for translational researchers investigating cognitive dysfunction, neuroprotection, and addiction models. By integrating breakthrough findings—such as the modulation of GLT-1 via the CB1-CREB signaling pathway in traumatic brain injury (TBI)—with practical workflow recommendations, this piece transcends conventional product overviews to serve as a roadmap for next-generation cannabinoid receptor research.

• AM 281 (SKU B6603): Scenario-Driven Guidance for Robust C...

  2026-03-26

  This article provides biomedical researchers and lab technicians with scenario-based solutions for common challenges in CB1 cannabinoid receptor assays, cell viability, and neuropharmacology workflows. By leveraging the high selectivity and reproducibility of AM 281 (SKU B6603), readers gain evidence-based insights for optimizing experimental design, protocol reliability, and product selection in memory impairment and neuroprotection studies.

• AM 281: Unlocking CB1 Receptor Antagonism for Cognitive D...

  2026-03-25

  Explore the unique neuropharmacological potential of AM 281, a selective CB1 cannabinoid receptor antagonist, in advancing memory impairment and traumatic brain injury research. This article delves into novel mechanistic insights and translational applications, setting it apart from existing guides on cannabinoid signaling.

• AM 281: Selective CB1 Receptor Antagonist for Neuropharma...

  2026-03-25

  AM 281 is a highly selective CB1 cannabinoid receptor antagonist and inverse agonist, offering nanomolar affinity for CB1 and robust selectivity over CB2. This compound enables precise dissection of the CB1 signaling pathway, making it vital for neuropharmacology and cognitive dysfunction research.

• AM 281: Selective CB1 Cannabinoid Receptor Antagonist for...

  2026-03-24

  AM 281 is a highly selective CB1 cannabinoid receptor antagonist and inverse agonist with potent nanomolar affinity, enabling precise modulation of the cannabinoid signaling pathway in neuropharmacology research. This article presents evidence-based benchmarks and practical workflow guidance for AM 281, highlighting its role in models of cognitive dysfunction, addiction, and traumatic brain injury.

• AM 281: Selective CB1 Receptor Antagonist for Neuropharma...

  2026-03-24

  AM 281 is a potent, selective CB1 cannabinoid receptor antagonist and inverse agonist, validated for use in neuropharmacology and memory impairment research. Its high affinity and selectivity for CB1 enable precise interrogation of cannabinoid signaling pathways and cognitive dysfunction models. This article clarifies its mechanism, application boundaries, and integration into modern neuropharmacological workflows.

• Rewiring the Cannabinoid Signaling Axis: Strategic Insigh...

  2026-03-23

  Translational neuroscience is converging on the cannabinoid signaling pathway as a critical regulator of memory, mood, and neuroprotection. This thought-leadership article provides mechanistic clarity and strategic guidance for investigators seeking to disrupt maladaptive CB1 receptor signaling in models of cognitive dysfunction and neurodegeneration. Uniting rigorous evidence—including new findings on GLT-1/CB1-CREB pathway crosstalk—with practical recommendations, we chart a roadmap for leveraging the selective CB1 antagonist and inverse agonist AM 281 (from APExBIO) to unlock next-generation discovery and translational impact.

• AM 281: Selective CB1 Antagonist for Neuropharmacology Re...

  2026-03-23

  AM 281 is a potent, selective CB1 cannabinoid receptor antagonist and inverse agonist that empowers neuropharmacology research targeting memory impairment, traumatic brain injury, and addiction-related cognitive dysfunction. Its high CB1 affinity and robust performance in experimental models uniquely position AM 281 as a gold-standard tool for dissecting cannabinoid receptor signaling pathways and optimizing translational workflows.

• AM 281: Advancing Precision in CB1 Receptor Antagonism fo...

  2026-03-22

  Explore how AM 281, a selective CB1 receptor antagonist, enables next-generation research into cognitive dysfunction, neuroprotection, and addiction. Discover unique mechanistic insights and translational applications, setting this cornerstone apart from existing guides.

• AM 281: Advancing CB1 Receptor Antagonism for Cognitive R...

  2026-03-21

  Explore how AM 281, a selective CB1 cannabinoid receptor antagonist, uniquely enables neuropharmacology research into memory impairment, TBI, and addiction. This article reveals novel mechanistic insights and translational strategies distinct from prior content.

450 records 23/30 page Previous Next First page 上5页 2122232425 下5页 Last page